Eli Lilly and Company (LLY)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Receivables turnover | 3.39 | 3.01 | 4.14 | 4.24 | 4.18 | |
| DSO | days | 107.58 | 121.25 | 88.19 | 86.01 | 87.39 |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 3.39
= 107.58
The Days Sales Outstanding (DSO) for Eli Lilly and Company shows a slight improvement from 87.39 days as of December 31, 2020, to 86.01 days as of December 31, 2021. However, there was a slight increase in DSO to 88.19 days as of December 31, 2022. A more significant uptick is observed as of December 31, 2023, where DSO jumps to 121.25 days, indicating a potential collection or accounts receivable management issue. By December 31, 2024, there is a modest reduction in DSO to 107.58 days, but the metric remains elevated compared to the previous years. Overall, the trend in DSO for Eli Lilly and Company suggests some variability in the efficiency of their accounts receivable collection process, warranting a closer examination of their receivables management strategies.
Peer comparison
Dec 31, 2024